Kolon Life Science Inc Asset Resilience Ratio
Kolon Life Science Inc asset resilience ratio. Kolon Life Science Inc (102940) has an Asset Resilience Ratio of 1.22% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Kolon Life Science Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kolon Life Science Inc (2016–2024)
Asset resilience ratio of Kolon Life Science Inc from 2016 to 2024. This chart shows how Kolon Life Science Inc's Asset Resilience Ratio has changed over time. Read 102940 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kolon Life Science Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 102940 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩7.33 Billion | 1.22% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩7.33 Billion | 1.22% |
Asset Resilience Insights
- Limited Liquidity: Kolon Life Science Inc maintains only 1.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Kolon Life Science Inc Industry Peers by Asset Resilience Ratio
Compare Kolon Life Science Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
Kolon Life Science Inc Asset Resilience Ratio by Year (2016–2024)
Kolon Life Science Inc asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Kolon Life Science Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.96% | ₩12.42 Billion ≈ $8.41 Million |
₩419.56 Billion ≈ $284.33 Million |
+0.54pp |
| 2023-12-31 | 2.42% | ₩7.48 Billion ≈ $5.07 Million |
₩309.44 Billion ≈ $209.70 Million |
+0.39pp |
| 2022-12-31 | 2.03% | ₩6.37 Billion ≈ $4.32 Million |
₩314.12 Billion ≈ $212.87 Million |
-9.87pp |
| 2021-12-31 | 11.89% | ₩27.91 Billion ≈ $18.91 Million |
₩234.66 Billion ≈ $159.02 Million |
+5.84pp |
| 2020-12-31 | 6.05% | ₩15.03 Billion ≈ $10.19 Million |
₩248.34 Billion ≈ $168.29 Million |
-1.46pp |
| 2019-12-31 | 7.51% | ₩20.91 Billion ≈ $14.17 Million |
₩278.29 Billion ≈ $188.60 Million |
+1.41pp |
| 2018-12-31 | 6.10% | ₩37.77 Billion ≈ $25.60 Million |
₩618.90 Billion ≈ $419.42 Million |
-4.89pp |
| 2017-12-31 | 11.00% | ₩78.83 Billion ≈ $53.42 Million |
₩716.80 Billion ≈ $485.76 Million |
-27.88pp |
| 2016-12-31 | 38.88% | ₩137.85 Billion ≈ $93.42 Million |
₩354.57 Billion ≈ $240.29 Million |
-- |
About Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more